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Abstract 
Many patients under therapy with recombinant human erythropoietin (rhuEPO) show 
resistance to the treatment, an effect likely associated with the accumulation of tissue 
factors, especially in renal and cardiovascular diseases. Hyperhomocysteinemia due to high 
serum levels of homocysteine has been suggested among the risk factors in those 
pathologies. Its main effect is the N-homocysteinylation of proteins due to the interaction 
between the highly reactive homocysteine thiolactone (HTL) and lysine residues. The aim of 
this study was to evaluate the effect of N-homocysteinylation on the erythropoietic and 
antiapoptotic abilities of EPO, which can be a consequence of structural changes in the 
modified protein. We found that both cellular functions were altered in the presence of HTL-
EPO. A decreased net positive charge of HTL-EPO was detected by capillary zone 
electrophoresis, while analysis of polyacrylamide gel electropherograms suggested 
formation of aggregates. Far-UV spectra, obtained by Circular Dichroism Spectroscopy, 
indicated a switch of the protein’s secondary structure from -helix to -sheet structures. 
Results of Congo red and Thioflavin T assays confirm the formation of repetitive β-sheet 
structures, which may account for aggregates. Accordingly, Dynamic Light Scattering 
analysis showed a markedly larger radius of the HTL-EPO structures, supporting the 
formation of soluble oligomers. These structural changes might interfere with the 
conformational adaptations necessary for efficient ligand-receptor interaction, thus affecting 
the proliferative and antiapoptotic functions of EPO. 
 
The present findings may contribute to explain the resistance exhibited by patients with 
cardio-renal syndrome to treatment with rhuEPO, as a consequence of structural 
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Introduction 
Erythropoietin (EPO) is the main hormone involved in the regulation and maintenance of a 
physiological number of erythrocytes. Therefore, therapy with recombinant human 
erythropoietin (rhuEPO) has been successfully used to treat the anemia associated with 
different pathologies. However, a significant number of patients have been reported to 
exhibit a deficient response. The uremic syndrome is likely one of the conditions leading to 
EPO resistance, and the administration of high doses of EPO to this specific population is 
associated with an increased risk of morbidity and mortality [1-3]. Tissue factors that 
accumulate in several pathological situations ─most of which were identified as uremic 
toxins─ have been linked to EPO resistance [4].  
 
Hyperhomocysteinemia is defined by the presence of high serum levels of homocysteine 
(Hcy), a sulfur-containing, non proteinogenic amino acid biosynthesized from methionine. 
This condition has been associated with an increased cardiovascular risk in the general 
population [5]. The major cause of high Hcy levels in chronic renal disease is the impairment 
of its metabolism by the kidney [6,7]. In patients on hemodialysis ─the main candidates to 
receive rhuEPO treatment─ the presence of hyperhomocysteinemia has been linked to a 
negative prognosis [8]. 
 
Different mechanisms have been proposed to explain the toxicity of Hcy in uremia [9]. 
Among them, a potential mechanism has been attributed to the alteration of protein structure 
by homocysteinylation [10,11]. While Hcy reacts with proteins causing S-homocysteinylation 
of cysteine residues, the highly reactive Hcy derivative, named homocysteine thiolactone 
(HTL), reacts with the ε-amino groups of lysine residues producing N-homocyteinylated 
proteins (Fig. 1) [10,12]. When plasma proteins are incubated in the presence of HTL, 
homocysteinylation occurs under physiological conditions and this may lead to protein 
damage [10].  
 
The functionality of proteins depends on their structural integrity. Several kinds of insults 
such as oxidative stress, ionizing radiation or drug exposure, as well as the 
pathophysiological accumulation of reactive metabolites in the body, can induce non-
enzymatic post-translational modifications in proteins, thus causing the alteration of their 
functional properties and denaturation. Besides, it has been reported that N-
homocysteinylation may cause protein aggregation, as documented for several proteins 
[10,13-18]. Although different hypothesis have been proposed to describe the pathological 
consequences of hyperhomocysteinemia in humans, the molecular mechanisms of protein 
dysfunction are yet poorly understood. 
 
The presence of 8 lysine residues in the primary structure of EPO makes it a potential target 
for N-homocysteinylation, particularly under severe hyperhomocysteinemia, when the levels 
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with EPO inducing functional alterations in the protein, and consequently leading to EPO 
therapy resistance. Therefore, this study was conducted to evaluate the possible effects of 
structural changes derived from the N-homocysteinylation of EPO on the biological activity of 
this protein in erythroid cells. We show that incubation of EPO with HTL not only impairs the 
antiapoptotic and erythropoietic functions of the protein, but concurrently brings about 




N-homocysteinylation of recombinant human erythropoietin 
It has been reported that HTL specifically reacts with lysine residues in the polypeptide chain 
and hence lysine-rich proteins are the potential major target of HTL. This covalent 
modification involves the formation of one homocystamide and the consequent addition of 
one thiol group to the protein, for each lysine residue reacting with HTL [12]. EPO was 
incubated with HTL in the following molar ratios: EPO:HTL 1:100 (HTL100EPO), 1:1000 
(HTL1000EPO) and 1:2000 (HTL2000EPO). As a first approach to detect the reaction of HTL 
with EPO, the Ellman’s assay was performed to quantify free sulfhydryl groups. HTL100EPO 
showed no significant difference with respect to the control EPO —incubated for the same 
period in the absence of HTL—, while the amount of free sulfhydryl groups in HTL1000EPO 
and HTL2000EPO was ten times higher than in the native protein (Fig. 2). 
 
Functional alterations of erythropoietin due to N-homocysteinylation 
In previous works, we demonstrated that the modification of EPO by carbamylation alters its 
erythropoietic action [19,20]. To evaluate the effect of protein N-homocysteinylation on the 
ability of rhuEPO to stimulate erythroid cell growth and survival, UT-7 cells were cultured in 
the presence of HTL-EPO samples.  
 
The UT-7 cell line, dependent on EPO to survive, failed to proliferate in 48 h-cultures in the 
presence of HTL1000EPO or HTL2000EPO. In contrast, HTL100EPO produced a similar effect to 
that of the native protein (Fig. 3A). Accordingly, only HTL100EPO was comparable to control 
EPO when cell viability was analyzed (Fig. 3B). As shown in Fig. 3C, the metabolic activity of 
cells treated with HTL1000EPO and HTL2000EPO was as low as that observed in cells cultured 
in the absence of the growth factor, and significantly lower than in cultures with EPO or 
HTL100EPO. Furthermore, the decrease in MTT signal as well as in the rate of cell 
proliferation appears to depend on the degree of modification sustained by EPO, as 
analyzed by the Ellman’s reaction. 
 
To determine whether N-homocysteinylation also affects protection of UT-7 cells by EPO, 
apoptosis was evaluated by fluorescent nuclear staining and phosphatidylserine 
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EPO samples (Fig. 3D-F). In line with the results of UT-7 cell proliferation, Fig. 3 shows an 
alteration of the antiapoptotic capacity of EPO when the molecule is modified by high 
concentrations of HTL.  
 
It is worth mentioning that control EPO, which was incubated in the absence of HTL for the 
same period and conditions as the HTL-treated samples, suffered no alterations in its ability 
to preserve cell viability, stimulate growth and prevent apoptosis. 
 
Effect of N-homocysteinylation on erythropoietin structure 
Electrophoretic mobility 
Since distinct functional abilities were detected between control EPO and the HTL-EPO 
samples, the following aim was to study if changes in the structure of EPO could explain the 
inhibition of its functions. 
 
In Capillary Zone Electrophoresis (CZE), N-homocysteinylation caused a delay in the 
migration time of EPO depending on the HTL concentration used (Fig. 4A). This was an 
expected finding, since the loss of positive charge due to N-homocysteinylation of lysine 
residues predicts a lower mobility in the system used. 
 
The isoelectric points of control EPO and HTL1000EPO were calculated by Capillary 
Isoelectrofocusing (CIEF), obtaining five peaks in the 4.25-5.11 pH range for control EPO 
and seven peaks with pIs between 4.32-5.15 for HTL1000EPO (Fig. 4B). Since rhuEPO is a 
heterogeneous mixture of isoforms, no single pI is available; therefore, changes in the pIs of 
each isoform after reaction with HTL cannot be identified by this analysis. A differential 
interaction of HTL with each EPO isoform may be expected as the amino acid residues are 
exposed to different carbohydrate environments. 
 
Control and treated EPO samples were also analyzed by native PAGE electrophoresis 
followed by silver staining (Fig. 5A). The electropherograms revealed several bands in the 
treated samples which exhibited markedly lower migration rates than the native EPO. These 
bands may account for modified proteins with different charge/mass ratios. Immunodetection 
allowed to identify such bands as EPO, as all the bands appearing on the gel (Fig. 5A) were 
positive for reaction with the anti-EPO antibody (Fig. 5B). These results suggest that 
treatment of EPO with a high HTL concentration gives rise to larger protein structures. In 
CZE, total protein charge has a high influence on molecule mobility, contrary to what 
happens in gel electrophoresis, where this parameter is affected by the charge/mass ratio 
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In order to explain the different results obtained with both techniques, we analyzed possible 
structural modifications on HTL-treated EPO. 
 
Circular Dichroism Spectroscopy (CD) 
Far-UV CD spectroscopy was used to explore the secondary structure of EPO after 
treatment with HTL. In the Far-UV CD spectra obtained in the 200-260 nm range, native 
EPO exhibited the typical spectrum of an α-helical protein with the characteristic minima at 
208 and 222 nm (Fig. 6A), in agreement with previously reported results for other 
commercial erythropoietins [21]. As shown in the figure, no significant changes were 
observed at a low HTL concentration (HTL100EPO), whereas in the presence of higher 
concentrations of HTL, EPO exhibited significant structural transitions, resulting in a 
pronounced alteration in its relative structural proportions (Fig. 6A, inset). HTL1000EPO and 
HTL2000EPO showed a negative CD signal with the contribution of a minimum at 216 nm, 
typical of a β-sheet conformation. These spectral changes may be due to the conversion of 
α-helix to repetitive β-sheet. Moreover, CD spectra deconvolution displayed a decrease in α-
helical content from 53% in EPO to 28% in HTL2000EPO with the concomitant increase in β-
sheet conformation from 5% to 18% (Fig. 6A, inset). 
 
Near-UV CD spectroscopy was employed to analyze modifications in the tertiary structure of 
the protein after HTL treatment. While the aromatic CD signal of HTL100EPO was only 
slightly modified, HTL1000EPO and HTL2000EPO exhibited a pronounced change in spectral 
shape (Fig. 6B). 
 
Intrinsic Fluorescence  
Intrinsic fluorescence spectra were recorded to study the environment of the three 
tryptophans in the EPO molecule. For this purpose, samples of native and HTL-modified 
EPO were analyzed at the same final concentration. No differences were observed in the 
maximum fluorescence wavelength of Trp among the different erythropoietin samples 
analyzed. Nevertheless, the intensities observed for HTL1000EPO and HTL2000EPO were 
higher than those of EPO and HTL100EPO (Fig. 7A). This indicates a lower quenching of Trp 
fluorescence due to modifications in the environment of these residues in the different HTL-
EPO preparations. This result suggests that as a consequence of N-homocysteinylation, 
tryptophans are more protected from quenchers, and confirms a change in the tertiary 
structure of the modified proteins. 
 
ANS Assays 
As an additional assay, we used spectrofluorometry to examine the binding of ANS to 
hydrophobic clusters on the protein’s surface. Binding of ANS to EPO was confirmed by the 
characteristic blue shift and the increase in ANS fluorescence emission (Fig. 7B). 
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increased ANS fluorescence intensity, indicative of the existence of hydrophobic surface 
areas exposed to the solvent when the repetitive β-sheet structure was formed.  
 
Congo red and Thioflavin T Assays 
For a better evaluation of the increase in β-sheet structures observed by CD after HTL 
treatment, the ability of samples to bind Congo red and Thioflavin T (ThT), two dyes usually 
used to monitor the formation of amyloid structures, was assayed (Fig. 7C and D). Unlike 
EPO and HTL100EPO, the incubation of HTL1000EPO and HTL2000EPO with the Congo red 
dye showed a spectral shift to higher wavelengths, which supports the formation of repetitive 
β-sheet structures previously observed in CD experiments. 
 
While a slight change in the ThT fluorescence spectrum was observed in the presence of 
HTL100EPO, a pronounced increase was detected when EPO was incubated with higher 
concentrations of HTL. This result confirms the formation of repetitive β-sheet structures in 
the HTL1000EPO and HTL2000EPO samples that may account for amyloid fibril precursors 
[13,22]. 
 
Dynamic Light Scattering (DLS) 
In order to confirm the presence of larger particles in samples of HTL-treated EPO, a DLS 
analysis was performed. The mean data of radius distribution corresponding to the control 
and the modified EPO molecules is shown in Fig. 8. While HTL100EPO presented a similar 
size than EPO, markedly larger radii were obtained for the modified proteins HTL1000EPO 
and HTL2000EPO, supporting the hypothesis of soluble oligomer formation. The values 
observed for mean radius suggest the presence of soluble oligomers rather than β-amyloid 
fibrils. It is worth mentioning that the radius obtained for native EPO is in agreement with 
data reported in the literature [21]. 
 
Discussion 
High serum levels of homocysteine (Hcy) have been found associated with an increased 
incidence of cardiovascular diseases ─including atherosclerosis [23] and thrombosis [24]─, 
with chronic kidney disease [6, 25] and with various neurodegenerative pathologies such as 
dementia and Parkinson’s [26] and Alzheimer’s [27] diseases.  
 
Methionyl-tRNA synthetase (MetRS) catalyzes the conversion of Hcy to a cyclic and highly 
reactive thioester (homocysteine thiolactone) which easily acylates free amino groups of 
protein lysine residues in a process referred to as protein N-homocysteinylation [12]. In this 
context, N-homocysteinylated plasma proteins were found significantly increased in end 
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It has been reported that the reaction of HTL with proteins results in the loss of their 
functions due to alterations in the molecular structure and to a higher sensitivity to oxidative 
damage [11]. This issue is specially important, since it has been described that in ESRD the 
prevalence of hyperhomocysteinemia is 85–100% [25].  
 
Erythropoietin is the main growth factor associated with the regulation of red blood cell 
production. Since expression of the EPO receptor and responsiveness to EPO were 
observed in non-hematopoietic tissues, this protein is also considered a survival factor for 
different non-erythroid cells [29,30].  
 
Taking the above mentioned into account, the aim of this work was to evaluate whether EPO 
could be a target for HTL, and if the functionality of the protein could be affected by N-
homocysteinylation. 
 
We found that EPO incubated with high concentrations of HTL (EPO:HTL at molar ratios 
1:1000 and 1:2000) not only failed to induce proliferation of the EPO-dependent UT-7 cell 
line, but was also unable to protect these cells from apoptosis (Fig. 3). These results indicate 
a loss of activity of the modified EPO, in agreement with reports showing that N-
homocysteinylation is associated with structural and functional alterations of different 
proteins [11,17,31]. 
 
We then went forward to analyze possible structural changes in the EPO molecule due to 
reaction with HTL, which could explain the detected loss of function. 
 
First, we compared the electrophoretic mobility of the modified proteins with respect to the 
unmodified EPO by Capillary Zone Electrophoresis (Fig. 4). The electropherograms showed 
a lower electrophoretic mobility for the modified proteins with an impaired biological function. 
This was an expected result, as the N-homocysteinylation of lysine residues accounts for a 
decrease in the positive net charge of the protein, despite the fact that a new amino group is 
added during the reaction. An explanation for the lower positive net charge observed in N-
homocysteinylated proteins was given by Jakubowski [10], who reported that the -amino 
group of lysine (pK=10.5) is much more basic than the α-amino group of Hcy bound to 
lysine, (εN(Hcy) lysine, pK=7.1). 
However, contrary to what was expected, the separation pattern of the modified proteins 
analyzed by polyacrylamide gel electrophoresis under native conditions showed bands of 
HTL-EPO with low electrophoretic mobility (Fig. 5A and 5B). One possible explanation for 
this phenomenon is the aggregation of the protein induced by N-homocysteinylation. In line 
with these results, many acidic proteins have been reported to form oligomers and 
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In order to evaluate possible modifications in the structure of EPO, intrinsic protein 
fluorescence emission spectra were used to analyze changes in the aromatic amino acid 
environment. As the concentration of HTL reacting with the protein increased, we observed a 
higher intensity of fluorescence without change in the emission maxima, confirming that EPO 
undergoes a structural modification (Fig. 7A). This particular behavior could be attributed to 
minor polarity changes in the surroundings of tryptophan residues and to the relocation of 
the tryptophan away from other residues that could act as fluorescence quenchers. It has 
been reported that residues W51 and W64 are buried within the core of the protein, while 
W88 appears to be partially exposed to the solvent [32]. Our results suggest that W88 is 
protected from the quencher as a consequence of the structural changes sustained by the 
modified EPO.  
 
To further assess the effect of HTL on the EPO molecule, CD spectra were analyzed, 
revealing significant alterations in the secondary structure of the protein (Fig. 6A). As a 
member of the hematopoietic growth factor family, the topology of EPO predominantly 
consists of a left-handed bundle of four α-helices [33], which was transformed into a β-sheet-
rich structure after exposure to HTL. Further gaining of a critical amount of β-sheets may 
give rise to the formation of soluble oligomers that could be precursors of fibril aggregates. In 
line with these results, the conversion of α-helices to β-sheets due to N-homocysteinylation, 
regardless of aggregate formation, has been previously reported for other proteins, such as 
bovine insulin [15], caseins [16] and α-lactalbumin [17].  
 
To elucidate whether N-homocysteinylation could induce the formation of β-sheet repetitive 
structures, the ability of EPO samples to bind Congo red and ThT was assayed. When EPO 
was treated with the highest concentrations of HTL, the observed change of the dye 
absorbance maximum (Fig. 7A) indicates the presence of β-sheet repetitive structures 
−possibly soluble oligomers─ that could account for amyloid fibril precursors. The results 
obtained by the ThT assay (Fig. 7B) are consistent with those of Congo red assay. The ANS 
binding capacity assay (Fig. 7B) indicated that buried hydrophobic surfaces become 
accessible to the solvent, an effect that was previously reported for β-sheet soluble 
oligomers comprised of other proteins [22], and for homocysteinylated proteins [17]. The 
formation of these soluble oligomers is compatible with the higher mean of radial distribution 
obtained by DLS for the HTL-treated erythropoietin samples (Fig. 8). This result supports the 
presence of large structures with low electrophoretic mobility in the gel electrophoresis 
assays presented in Figure 5. 
 
Alterations in the non-covalent interactions that maintain the structure of a protein may lead 
to its misfolding or unfolding. This may in turn induce interactions between exposed 
hydrophobic zones of neighbouring proteins, leading to either amorphous or more structured 
aggregates like amyloid fibrils. The results from Paoli et al [13] reveal that even a low level of 
N-homocysteinylation induced mild conformational changes in bovine serum albumin (BSA). 
In the presence of HTL, the structure of BSA was converted into a partially unfolded 
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reorganization, leading to the formation of amyloid-like fibrils. There are many examples of 
peptides or folded proteins, of which some are associated with pathologies, where the 
soluble oligomers may accumulate or act as fibril precursors [22,34-39]. Based on this 
knowledge, the loss of biological function observed in EPO after modification with HTL could 
be explained by misfolding of the protein. This results in the exposure of hydrophobic zones 
which would ultimately allow the formation of soluble oligomers. An updated review [40] 
discusses the formation of toxic multimers, aggregates or amyloids resulting from 
incorporation of HTL into proteins. In this context, this reaction has been suggested as an 
independent risk factor for different pathologies, particularly neurodegenerative diseases 
[13,41,42] 
 
In this work, we report for the first time that N-homocysteinylation destabilizes the structure 
of the growth factor erythropoietin, causing the conversion of its α-helices to β-sheet 
repetitive structures with a high tendency to form soluble oligomers. Based on these results, 
we suggest that the structural changes in the molecule impair the spatial adaptation required 
for an efficient ligand-receptor interaction, thus affecting the proliferative and antiapoptotic 
functions of EPO. 
 
Although further investigation is required, the present findings may contribute to explain the 
resistance of patients with cardiovascular and renal diseases to EPO treatment, which is 
frequently associated with hyperhomocysteinemia and consequently, with protein N-
homocysteinylation.  
 
Materials and Methods 
Materials 
All chemicals were of analytical grade. Iscove's Modified Dulbecco's Medium and the 
penicillin–streptomycin antibiotic mixture were obtained from Gibco BRL. 3-(4,5-Dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), 5,5´-dithiobis(2-nitrobenzoic acid) 
(Ellman’s Reagent), Hoechst 33258 dye, L-Homocysteine thiolactone hydrochloride, 25% 
glutaraldehyde solution, dithiothreitol (DTT) solution, Congo Red dye, 8-Anilino-1-
naphthalenesulfonic acid (ANS), Trypan Blue Solution (0.4%) and horseradish peroxidase-
conjugated anti-Mouse IgG (A4416) were obtained from Sigma-Aldrich. The primary 
antibody against EPO (B4-sc5290) was from Santa Cruz Biotechnologies. The Annexin V-
FITC Apoptosis Detection Kit I was from BD Transduction Laboratories. The Carrier 
Ampholytes pH range 3.0–10.0 were from Pharmalyte GE-Healthcare Bio-Sciences AB. 
Fetal bovine serum (FBS) was purchased from Natocor (Argentina). Recombinant human 
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Cell cultures 
The human UT-7 cell line, that shows growth dependence on EPO, was kindly provided by 
Dr. Patrick Mayeux (Cochin Hospital, Paris, France). Cells were maintained in Iscove's 
Modified Dulbecco's Medium supplemented with 10% FBS, 100 U/mL penicillin, 100 μg/mL 
streptomycin and 1 U/mL EPO. Cell cultures were developed at 37 °C in an atmosphere 
containing 5% CO2 and 100% humidity [43]. The medium was replaced every 2–3 days. Cell 
viability and proliferation were routinely evaluated by the Trypan blue exclusion test. 
 
Protein N-homocysteinylation 
Recombinant human erythropoietin (specific activity: 125 IU/µg) with Mr of 30243 as 
determined by MALDI-TOF MS, was incubated (24 h, 37 °C) in the presence of different 
concentrations of HTL (EPO:HTL molar ratios: 1:100, 1:1000 and 1:2000) in phosphate 
buffered saline (PBS). After the incubation period, the remaining free HTL was eliminated by 
ultrafiltration and washing with PBS using an Amicon Ultra-4 centrifugal filter (3 kDa cut-off, 
Merck Millipore) and final protein concentrations were measured (Nanodrop 2000, Thermo 
Scientific). EPO samples subjected to a similar incubation process in the absence of HTL 
were used as controls in all the experiments. Analyses were performed using three 
independent HTL-EPO batches.  
 
Protein sulfhydryl estimation  
The efficiency of EPO N-homocysteinylation was monitored by detecting the increase in 
protein sulfhydryl groups. The Ellman’s reaction was applied to detect free sulfhydryl groups 
in HTL-EPO and control samples using the Ellman’s Reagent. According to the 
manufacturer’s instructions, 250 µL of each sample were added to 50 µL of Ellman’s 
Reagent Solution and 2.5 mL of Reaction Buffer and incubated at room temperature for 15 
min. Absorbance was measured at 412 nm. The amount of 2-nitro-5-thiobenzoic acid 
released was estimated from the molar extinction coefficient (ε) of 14,150 M-1 cm-1, and the 
results were expressed as µmoles of free sulfydryl per µmol of protein. 
 
MTT assay  
The MTT dye reduction assay, which measures metabolic activity thus reflecting cell viability, 
was performed as previously described [44]. Cell cultures were developed in 35 mm Petri 
dishes at a density of 2x105 cells/mL. The medium was removed and cells were incubated 
with MTT at 0.5 mg/mL final concentration (2 h, 37 °C). After centrifugation (10 min, 9500 
xg), the supernatant was removed and the pellet washed with PBS. Finally, 0.04 M HCl in 
isopropanol (100 μL) was added to dissolve the blue formazan product (reduced MTT), 
which was quantified by measuring absorbance at 570 nm (with reference to 660 nm) in a 
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Fluorescent nuclear staining of apoptotic cells 
Cells (2 x105 cells/mL) were cultured on slide covers placed in 35 mm Petri dishes. After 
fixation with Carnoy’s solution (methanol:acetic acid, 3:1 v/v) for 10 min at room 
temperature, the samples were dried at 20 °C, and later exposed to 0.05 g/L Hoechst 33258 
dye in PBS for 10 min at room temperature, washed three times with 18 MΩ water and 
finally mounted with 50% (v/v) glycerol in PBS. Fluorescent nuclei with apoptotic 
characteristics were detected by fluorescence microscopy at 365 nm (UV) (Zeiss Axiovert 
135). Images were acquired using a Nikon Coolpix 5000 camera and digitalized with the 
AxioVision Software. Differential counting of nuclei was performed by analyzing at least 500 
cells [44]. 
 
Apoptosis detection by Flow Cytometry 
Annexin V and propidium iodide (PI) analysis allows the detection of different stages of 
apoptosis. The assay was performed according to the instructions of the commercial kit. 
Briefly, cells were washed twice with cold PBS and then suspended (1x106/mL) in binding 
buffer (0.01 M Hepes/NaOH pH 7.4, 0.14 M NaCl, 2.5 mM CaCl2). Annexin V-FITC (5 µL) 
and PI (5 µL) were added to 100 µL of cell suspension, which was incubated for 15 min at 25 
°C in the dark. After addition of 400 µL of binding buffer, events were acquired in a flow 
cytometer equipped with a 488 nm argon laser (FACSAria II, Becton-Dickinson). The 
Cyflogic v1.2.1 software was used for data analysis. 
 
Capillary Zone Electrophoresis 
Sample analysis was performed at pH 9.9 (150 mM sodium borate buffer) at 6.7 KV (current 
intensity 50 µA) in a P/ACE MDQ Capillary Electrophoresis System (Beckman Coulter), 
equipped with a Photo Diode Array (PDA) detector. The sample hydrodynamic injection was 
performed during 2.5 sec at a pressure of 0.4 psi in a fused silica capillary of 40 cm length 
(effective length 30 cm) and 50 µm internal diameter. Electropherograms showing migration 
time vs. absorbance at 214 nm were obtained at 25 °C. 
 
Capillary Isoelectric Focusing (CIEF) [45]  
EPO solution in 20 mM Tris pH 8.0 buffer was concentrated in an Amicon Ultra-4 centrifugal 
filter (3 kDa cut-off, Merck Millipore) to replace PBS.  
 
All CIEF separations were performed using a P/ACE MDQ Capillary Electrophoresis System 
(Beckman Coulter) equipped with a UV detector and a 280 nm filter. The installed Neutral 
Capillary (Beckman Coulter, 30.2 cm long, 20 cm effective length, 50 µm i.d) was maintained 
at 20 °C during assays. The sample mix ─with or without EPO─, consisting of a mixture of 
pH 3-10 Carrier Ampholytes, iminodiacetic acid (200 mM), peptide pI markers and 6M urea-
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carried out at field strength of 25 kV for 6 min in the reverse polarity setting with 200 mM 
phosphoric acid as anolyte, and 300 mM sodium hydroxide as catholyte. The focused peaks 
were chemically mobilized across the detection window by replacing the catholyte vial with a 
100 mM ammonium hydroxide solution, and then applying a field strength of 30 kV for 30 
min in the reverse polarity setting. The focused protein bands were detected by absorbance 
at 280 nm. Data were collected and analyzed using the 32 Karat™ Software.  
 
Electrophoresis and Western blotting 
Electrophoresis under alkaline nondenaturing conditions using Tris-glycine buffer pH 8.3 (25 
mM Tris, 192 mM glycine) was run in a Miniprotean III electrophoretic system (BioRad) using 
10% polyacrylamide gels. At the end, two procedures were followed, a) silver staining and b) 
Western blotting. 
 
a) Nitrate silver staining. The gel was treated with 40% methanol-7% acetic acid solution (30 
min) and with 5% methanol-7% acetic acid solution (7 min). After removing the solutions, the 
gel was immersed in 10% glutaraldehyde (30 min, room temperature). This solution was 
discarded and the gel was washed with various changes of water during an hour. Then, a 5 
µg/mL DTT solution was added and after 30 min replaced by the silver nitrate solution (0.1% 
w/v) for additional 30 min. After removing the silver solution, the developing solution (3% 
sodium carbonate, 0.019% formaldehyde) was added until the bands appeared. The process 
was stopped by addition of 2.3 M sodium citrate. 
 
b) Western blotting. After gel electrophoresis, protein samples were electroblotted onto a 
nitrocellulose membrane during 1.5 h (transfer buffer: 25 mM Tris, 195 mM glycine, 0.05% 
SDS, pH 8.3, and 20%, v/v, methanol). Membranes were blocked by 1 h incubation in Tris 
Buffered Saline (TBS: 25 mM Tris, 137 mM NaCl, 3 mM KCl, pH 7.4) containing 0.1% 
Tween 20 and 0.5% skim-milk powder [40], and then incubated with appropriate 
concentrations of anti EPO antibody. After washing with TBS–0.1% Tween 20, the 
immunoblots were probed with adequate peroxidase-conjugated secondary antibody 
(1:1000) for 1 h at 20 °C and washed. Antigen-antibody complex signals were detected by 
enhanced chemiluminiscence in a G:BOX Chemi system and digitalized using the GeneSys 
software (Syngene). 
 
Circular dichroism (CD) 
In order to assess the effect of HTL treatment on the secondary and tertiary structure of 
EPO, CD measurements were carried out on a Jasco J-815 spectropolarimeter. CD spectra 
in the far-UV and near-UV region were collected using a Peltier temperature-controlled 
sample holder at 25 °C in a 0.1-cm path length cell in 25 mM buffer solution. Each spectrum 
was repeated at least four times. Mean Residual Ellipticity ([]MRW (deg cm
2dmol-1res-1) was 
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Where  is ellipticity in millidegrees, l is the cuvette pathlength in cm, N is the number of 
residues and C is the molar concentration. 
 
We employed the K2D3 algorithm (http:://k2d3.ogic.ca/) to deconvolute far-UV CD spectrum 
in order to obtain experimental secondary structure contributions. 
 
Congo red binding assay 
A 5 µM final protein concentration of each EPO sample was diluted in PBS containing 2 µM 
Congo red (CR). Absorption spectra were acquired between 450–650 nm using a UV/Visible 
spectrophotometer (JascoV650) at 25 °C, with a 10-mm-pathlength cuvette. The spectrum of 
the protein aliquot in PBS buffer was subtracted from the spectrum of the protein solution in 
PBS with the addition of CR. The same procedure was followed for each treatment. 
 
Intrinsic, ANS and Thioflavin T fluorescence emission 
Fluorescence emission spectra of the samples (10 µM) were obtained in an Aminco-
Bowman spectrofluorimeter. Proteins were excited at 295 nm and the emission spectra were 
recorded in the 310-400 nm wavelength region. 
 
For ANS (8-Anilino-1-naphthalenesulfonic acid) experiments, the excitation wavelength was 
350 nm and emission spectra were recorded from 400 to 600 nm using an Aminco-Bowman 
spectrofluorimeter. Protein concentration was kept at 10 µM and ANS concentration was 100 
µM. Blanks were subtracted from each sample. Each spectrum was repeated at least three 
times. 
 
For ThT experiments, the excitation wavelength was 435 nm and emission spectra were 
recorded from 460 to 600 nm using an Aminco-Bowman spectrofluorimeter. Protein 
concentration was kept at 10 µM and ThT concentration was 20 µM. 
 
Dynamic Light Scattering (DLS)  
DLS provides information of the speed at which particles diffuse due to Brownian motion. 
DLS measurements of control and HTL-treated EPO samples were performed in PBS buffer 
in a Zetasizer Nano S DLS device (Malvern Instruments). Protein concentration was kept at 
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samples to higher values. Each sample was measured ten times with ten runs per 
measurement. The temperature was maintained at 25 °C by a Peltier control system. 




Statistical analysis was performed with the GraphPad Prism software (GraphPad Software 
Inc.). Whenever applied, ANOVA and Kruskal-Wallis one-way analysis of variance were 
followed by Dunnet’s or Dunn’s test for comparison among groups, respectively. Least 
significant difference with P<0.05 was considered the criterion for statistical significance. 
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Figure 1. Schematic representation of the reaction between homocysteine thiolactone and 
the ε-amino group of a lysine residue (Based on the mechanism of acylation of protein lysine 
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Figure 2. N-homocysteinylation efficiency. The Ellman’s reagent interacts with free sulfhydryl 
groups giving a colored reaction. Results are reported as µmoles of free sulfhydryl per µmol 
of protein. Free sulfhydryl, incorporated into EPO by N-homocysteinylation, increase as the 
concentration of HTL rises (Kruskal-Wallis and Dunn’s multiple comparisons test. Significant 
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Figure 3. Effect of N-homocysteinylation on EPO functions. EPO-dependent UT-7 cells were 
cultured for 48 h in the presence of HTL-treated or untreated EPO samples (8 ng/mL final 
concentration). The Trypan Blue Assay was used to evaluate cell proliferation (A) and 
viability (B). Incubation in the presence of HTL100EPO allowed cells to proliferate at a similar 
level as that of control EPO, while treatments with HTL1000EPO or HTL2000EPO failed to 
induce cell proliferation. C) Metabolic activity of UT-7 cells was analyzed by the MTT Assay. 
The results were in accordance with those of cell proliferation and viability. Statistical 
analysis by ANOVA followed by Dunnet’s multiple comparison test. Significant differences: 
*P<0.05, **P<0.01, Mean ± SEM, n=8. D) Phosphatidylserine translocation was used to 
evaluate apoptosis by flow cytometry. Protein N-homocysteinylation produced by high HTL 
concentrations affected the antiapoptotic action of EPO. E-F) Apoptosis was also evaluated 
by fluorescence microscopy after Hoechst staining (Microphotographs 400×, scale bar: 45 
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HTL2000EPO-treated cultures compared with those treated with control EPO or HTL100EPO 
(Kruskal-Wallis followed by Dunn’s multiple comparisons test. Significant differences: 
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Figure 4. Capillary Electrophoresis. A) CZE was used to evaluate possible changes in the 
charge/mass ratio of the molecule after N-homocysteinylation. As HTL interacts with lysine 
residues, the net positive charge of EPO diminishes causing a delay in the migration time of 
HTL-EPO when compared with the unmodified EPO (EPO: 4.17 min, HTL100EPO: 4.25 min, 
HTL1000EPO:4.60 min and HTL2000EPO: 4.58 min). B) CIEF analysis shows similar pI ranges 
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Figure 5. PAGE electrophoretic mobility of EPO. Proteins analyzed by (A) PAGE under 
native conditions were detected by silver staining (two different samples of HTL100EPO were 
applied) and (B) Western blotting with an anti-EPO antibody. When treated with high HTL 
concentrations, the N-homocysteinylated EPO forms larger structures which tend to 
decrease the rate of protein migration. The gel and immunoblot shown are representative of 
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Figure 6. Circular Dichroism spectra of EPO. A) Far-UV Circular Dichroism spectra were 
used to evaluate the secondary structure of proteins. HTL1000EPO and HTL2000EPO showed 
a decreased percentage of helical content and a concomitant increase in the percentage of 
β-sheet structural composition. The percentages of -helix and -strand in each sample 
were plotted with the K2D3 algorithm (inset). B) Near-UV CD spectra were used to analyze 
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Figure 7. Intrinsic fluorescence spectra, ANS binding, Congo red and Thioflavin T assays. A) 
Intrinsic fluorescence spectra were obtained to evaluate possible alterations in the local 
environment of the proteins due to N-homocysteinylation. Higher fluorescence intensity was 
observed for the proteins treated with high HTL concentrations, although no changes in the 
maximal emission spectrum were detected. B) The appearance of a hydrophobic surface 
area was analyzed by ANS-binding experiments. A marked increase in ANS binding was 
detected in the HTL1000EPO and HTL2000EPO samples. C) The Congo red assay showed the 
presence of repetitive β-sheet structures. Unlike EPO and HTL100EPO, HTL1000EPO and 
HTL2000EPO shifted their maximum absorbance to higher wavelengths. D) The Thioflavin T 
assay also indicates the presence of repetitive β-sheet structures inthe HTL1000EPO and 
HTL2000EPO samples by the increase of absorbance and the shift of their maximum 
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Figure 8. Hydrodynamic radius of HTL-treated EPO. The values represent Mean ± SD of 
radius distribution corresponding to the control and modified EPO particles. Each sample 
was measured 10 times with 10 runs/measurement. The values for the different EPO 
samples were EPO: 3.48±0.14 nm; HTL100EPO:3.76±0.46 nm; HTL1000EPO: 9.68±0.34 nm; 
HTL2000EPO: 9.80±0.39 nm. 
